Poxviruses and immune evasion

Annual Review of Immunology

Volumn 21, Issue , 2003, Pages 377-423

  Seet, Bruce T ^a   Johnston, J B ^b   Brunetti, Craig R ^b   Barrett, John W ^b   Everett, Helen ^b   Cameron, Cheryl ^a   Sypula, Joanna ^a   Nazarian, Steven H ^a   Lucas, Alexandra ^b   McFadden, Grant ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Apoptosis; Cell mediated immunity; Inflammation; Viroceptor; Virokine

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BINDING PROTEIN; CASPASE INHIBITOR; CHEMOKINE; CHEMOKINE BINDING PROTEIN TYPE 2; COMPLEMENT; CYTOKINE; EPIDERMAL GROWTH FACTOR DERIVATIVE; GAMMA INTERFERON RECEPTOR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; PROTEIN MC 148 R; PROTEIN MT 7; SEMAPHORIN; SERINE PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS PROTEIN; VIRUS RECEPTOR;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BINDING AFFINITY; CELL ACTIVITY; CELLULAR IMMUNITY; DNA VIRUS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; GENE ACTIVITY; GENE SEQUENCE; GENOME ANALYSIS; HOST; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INHIBITION KINETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROENVIRONMENT; NONHUMAN; OXIDATIVE STRESS; POXVIRUS; POXVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; VIRUS GENE; VIRUS GENOME; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; GENETICS; IMMUNOLOGY; METABOLISM; PATHOGENICITY; VIROLOGY;

ANIMALS; APOPTOSIS; CHEMOKINES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; GENOME, VIRAL; HUMANS; IMMUNITY, CELLULAR; INTERFERONS; MODELS, IMMUNOLOGICAL; POXVIRIDAE; POXVIRIDAE INFECTIONS; SIGNAL TRANSDUCTION; VIRAL PROTEINS;

EID: 0013098971     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.21.120601.141049     Document Type: Review

References (277)

1. Alcamí A, Koszinowski UH. 2000. Viral mechanisms of immune evasion. Immunol. Today 21:447-55
2. McFadden G, Murphy PM. 2000. Host-related immunomodulators encoded by poxviruses and herpesviruses. Curr. Opin. Microbiol. 3:371-78
3. Nash P, Barrett J, Cao J-X, Hota-Mitchell S, Lalani AS, et al. 1999. Immunomodulation by viruses: the myxoma virus story. Immunol. Rev. 168:103-20
4. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. 2000. Viral subversion of the immune system. Annu. Rev. Immunol. 18:861-926
5. Moss B, Shisler JL. 2001. Immunology 101 at poxvirus U: immune evasion genes. Semin. Immunol. 13:59-66
6. Smith GL. 2000. Secreted poxvirus proteins that interact with the immune system. In Effects of Microbes on the Immune System, ed. MW Cunningham, RS Fujinami, pp. 491-507. Philadelphia: Lippincott Williams & Wilkins
7. Smith GL. 1999. Vaccinia virus immune evasion. Immunol. Lett. 65:55-62
8. Barry M, McFadden G. 1997. Virus encoded cytokines and cytokine receptors. Parasitology 115:S89-100
9. Barry M, McFadden G. 1997. Virokines and viroceptors. In Cytokines in Health and Disease, ed. DG Remick, JS Friedland, pp. 251-61. New York: Marcel Dekker
10. Haig DM. 2001. Subversion and piracy: DNA viruses and immune evasion. Res. Vet. Sci. 70:205-19
11. Moss B. 2001. Poxviridae: the viruses and their replication. In Fields Virology, ed. DM Knipe, PM Howley, 2:2849-83. Philadelphia: Lippincott Williams & Wilkins. 4th ed.
12. Afonso CL, Tulman ER, Lu Z, Zsak L, Kutish GF, et al. 2000. The genome of fowlpox virus. J. Virol. 74:3815-31
13. Shchelkunov SN, Massung RF, Esposito JJ. 1995. Comparison of the genome DNA sequences of Bangladesh-1975 and India-1967 variola viruses. Virus Res. 36:107-18
14. Willer D, McFadden G, Evans DH. 1999. The complete genome sequence of Shope (rabbit) fibroma virus. Virology 264:319-43
15. Massung RF, Liu LI, Qi J, Knight JC, Yuran TE, et al. 1994. Analysis of the complete genome of smallpox variola major virus strain Bangladesh-1975. Virology 201:215-40
16. Shchelkunov SN, Totmenin AV, Loparev VN, Safronov PE Gutorov VV, et al. 2000. Alastrim smallpox variola minor virus genome DNA sequences. Virology 266:361-86
17. Cameron C, Hota-Mitchell S, Chen L, Barrett J, Cao J-X, et al. 1999. The complete DNA sequence ofmyxoma virus. Virology 264:298-318
18. Everett H, McFadden G. 2001. Viral proteins and the mitochondrial apoptotic checkpoint. Cytokine Growth Factor Rev. 12:181-88
19. Guerin J-L, Gelfi J, Bouillier S, Delverdier M, Bellanger F-A, et al. 2002. Myxoma virus leukemia-associated protein is responsible for major histocompatibility complex class I and Fas-CD95 down-regulation and defines scrapins, a new group of surface cellular receptor abductor proteins. J. Virol. 76:2912-23
20. Afonso CL, Tulman ER, Lu Z, Zsak L, Osorio FA, et al. 2002. The genome of swinepox virus. J. Virol. 76:783-90
21. Lee H-J, Essani K, Smith GL. 2001. The genome sequence of yaba-like disease virus, a yatapoxvirus. Virology 281:170-92
22. Senkevich TG, Koonin EV, Bugert JJ, Darai G, Moss B. 1997. The genome of molluscum contagiosum virus: analysis and comparison with other poxviruses. Virology 233:19-42
23. Buller RLM, Palumbo GJ. 1991. Poxvirus pathogenesis. Microbiol. Rev. 55:80-122
24. Barry M, Bleackley C. 2002. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. 2:401-9
25. McFadden G, Kane K. 1994. How DNA viruses perturb functional MHC expression to alter immune recognition. In Advances in Cancer Research, ed. GF Vandewoude, G Klein, 63:117-209. San Diego: Academic
26. Boshkov LK, Macen JL, McFadden G. 1992. Virus-induced loss of class I major histocompatibility antigens from the surface of cells infected with myxoma virus and malignant rabbit fibroma virus. J. Immunol. 148:881-87
27. Coscoy L, Ganem D. 2000. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci. USA 97:8051-56
28. Ishido S, Choi JK, Lee BS, Wang C, De-Maria M, et al. 2000. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 13:365-74
29. Zuñiga MC, Hong W, Barry M, McFadden G. 1999. Endosomal/lysosomal retention and degradation of major histocompatibility complex class I molecules is induced by myxoma virus. Virology 261:180-92
30. Senkevich TG, Bugert JJ, Sisler JR, Koonin EV, Darai G, et al. 1996. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 273:813-16
31. Senkevich TG, Moss B. 1998. Domain structure, intracellular trafficking, and beta-2-microglobulin binding of a major histocompatibility complex class I homolog encoded by molluscum contagiosum virus. Virology 250:397-407
32. + T lymphocytes. J. Virol. 69:5243-51
33. Muller-Eberhard HJ. 1988. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57:321-47
34. Lindahl G, Sjobring U, Johnsson E. 2000. Human complement regulators: a major target for pathogenic microorganisms. Curr. Opin. Immunol. 12:44-51
35. Howard J, Justus DE, Totmenin AV, Shchelkunov S, Kotwal GJ. 1998. Molecular mimicry of the inflammation modulatory proteins (IMPs) of poxviruses: evasion of the inflammatory response to preserve viral habitat. J. Leukoc. Biol. 64:68-71
36. Kotwal GJ, Moss B. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335:176-78
37. Kotwal GJ, Isaacs SN, McKenzie R, Frank MM, et al. 1990. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250:827-30
38. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM. 1992. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166:1245-50
39. Sahu A, Isaacs SN, Soulika AM, Lambris JD. 1998. Interaction of vaccinia virus complement control protein with human complement proteins - factor I-mediated degradation of C3b to Ic3b(1) inactivates the alternative complement pathway. J. Immunol. 160:5596-604
40. Isaacs SN, Kotwal GJ, Moss B. 1992. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc. Natl. Acad. Sci. USA 89:628-32
41. Murthy KH, Smith SA, Ganesh VK, Judge KW, Mullin N, et al. 2001. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104:301-11
42. Reynolds D, Keeling K, Molestina R, Srisatajluk R, Butterfield JHJ, et al. 1999. Heparin binding activity of vaccinia virus complement control protein confers additional properties of uptake by mast cells and attachment to endothelial cells. In Advances in Animal Virology, ed. S Jameel, L Villareal, pp. 337-43. New Delhi: Oxford/IBN
43. Smith SA, Mullin NP, Parkinson J, Shchelkunov SN, Totmenin AV, et al. 2000. Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense. J. Virol. 74:5659-66
44. Henderson CE, Bromek K, Mullin NP, Smith BO, Uhrin D, et al. 2001. Solution structure and dynamics of the central CCP module pair of a poxvirus complement control protein. J. Mol. Biol. 307:323-39
45. Johnson AA, Rosengard AM, Skjødt K, Ahearn JM, Leslie RGQ. 1999. The structural basis for complement receptor type 2 (CCR, CD21)-mediated alternative pathway activation of complement: studies with CR2 deletion mutants and vaccinia virus complement-control protein-CR2 chimeras. Eur. J. Immunol. 29:3837-44
46. Kirkitadze MD, Henderson C, Price NC, Kelly SM, Mullin NP, et al. 1999. Central modules of the vaccinia virus complement control protein are not in extensive contact. Biochem. J. 344:167-75
47. Rosengard AM, Alonso LC, Korb LC, Baldwin WM III, Sanfilippo F, et al. 1999. Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). Mol. Immunol. 36:685-97
48. Al-Mohanna F, Parhar R, Kotwal GJ. 2001. Vaccinia virus complement control protein is capable of protecting xenoendothelial cells from antibody binding and killing by human complement and cytotoxic cells. Transplantation 71:796-801
49. Anderson JB, Smith SA, Kotwal GJ. 2002. Vaccinia virus complement control protein inhibits hyperacute xenorejection. Transplant. Proc. 34:1083-85
50. Uvarova EA, Shchelkunov SN. 2001. Species-specific differences in the structure of orthopoxvirus complement-binding protein. Virus Res. 81:39-45
51. Miller CG, Shchelkunov SN, Kotwal GJ. 1997. The cowpox virus-encoded homolog of the vaccinia virus complement control protein is an inflammation modulatory protein. Virology 229:126-33
52. Kotwal GJ, Miller CG, Justus DE. 1998. The inflammation modulatory protein (IMP) of cowpox virus drastically diminishes the tissue damage by down-regulating cellular infiltration resulting from complement activation. Mol. Cell. Biochem. 185:39-46
53. Miller CG, Justus DE, Jayaraman S, Kotwal G J. 1995. Severe and prolonged inflammatory response to localized cowpox virus infection in footpads of C5-deficient mice: Investigation of the role of host complement in poxvirus pathogenesis. Cell. Immunol. 162:326-32
54. Rosengard AM, Liu Y, Nie Z, Jimenez R. 2002. Variola virus immune evasion design: expression of a highly efficient inhibitor of human complement. Proc. Natl. Acad. Sci. USA 99:8808-13
55. Engelstad M, Howard ST, Smith GL. 1992. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 188:801-10
56. Takahashi-Nishimaki F, Funahashi S, Miki K, Hashizume S, Sugimoto M. 1991. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology 181:158-64
57. Engelstad M, Smith GL. 1993. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence. Virology 194:627-37
58. Wolffe EJ, Isaacs SN, Moss B. 1993. Deletion of the vaccinia virus B5R-gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination. J. Virol. 67:4732-41
59. Sanderson CM, Frischknecht F, Way M, Hollinshead M, Smith GL. 1998. Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. J. Gen. Virol. 79:1415-25
60. Mathew E, Sanderson CM, Hollinshead M, Smith GL. 1998. The extracellular domain of vaccinia virus protein B5r affects plaque phenotype, extracellular enveloped virus release, and intracellular actin tail formation. J. Virol. 72:2429-38
61. Mathew EC, Sanderson CM, Hollinshead R, Smith GL. 2001. A mutational analysis of the vaccinia virus B5R protein. J. Gen. Virol. 82:1199-213
62. Rodger G, Smith GL. 2002. Replacing the SCR domains of vaccinia virus protein B5R with EGFP causes a reduction in plaque size and actin tail formation but enveloped virions are still transported to the cell surface. J. Gen. Virol. 83:323-32
63. Ward BM, Moss B. 2000. Golgi network targeting and plasma membrane internalization signals in vaccinia virus B5R envelope protein. J. Virol. 74:3771-80
64. Ward BM, Moss B. 2001. Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera. J. Virol. 75:4802-13
65. Herrera E, Lorenzo MD, Blasco R, Isaacs SN. 1998. Functional analysis of vaccinia virus B5R protein: essential role in virus envelopment is independent of a large portion of the extracellular domain. J. Virol. 72:294-302
66. Law M, Smith GL. 2001. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280:132-42
67. Vanderplasschen A, Matthew E, Hollinshead M, Sim RB, Smith GL. 1998. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc. Natl. Acad. Sci. USA 95:7544-49
68. Sen GC. 2001. Viruses and interferon. Annu. Rev. Microbiol. 55:255-81
69. Samuel CE. 2001. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:778-809
70. Smith GL, Symons JA, Alcamí A. 1998. Poxviruses: interfering with interferon. Semin. Virol. 8:409-18
71. Harris N, Buller RML, Karupiah G. 1995. Gamma intereron-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J. Virol. 69:910-15
72. Karupiah G, Fredrickson TN, Holmes KL, Khairallah LH, Buller RML. 1993. Importance of interferons in recovery from mousepox. J. Virol. 67:4214-26
73. Melková A, Esteban M. 1994. Interferon-γ severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology 198:731-35
74. Karupiah G, Blanden RV, Ramshaw IA. 1990. Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/ interleukin 2 infection. J. Exp. Med. 172:1495-503
75. Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA. 1990. Immuno-deficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur. J. Immunol. 20:157-61
76. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, et al. 1994. Functional role of type I and type II interferons in antiviral defense. Science 264:1918-21
77. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, et al. 1993. Immune response in mice that lack the interferon-γ receptor. Science 259:1742-45
78. van den Broek MF, Muller U, Huang S, Aguet M, Zinkernagel RM. 1995. Antiviral defense in mice lacking both α/β and γ interferon receptors. J. Virol. 69:4792-96
79. Upton C, Mossman K, McFadden G. 1992. Encoding of a homolog of the interferon-γ receptor by myxoma virus. Science 258:1369-72
80. Mossman K, Upton C, Buller RM, McFadden G, 1995. Species specificity of ectromelia virus and vaccinia virus interferon-γ binding proteins. Virology 208:762-69
81. Alcamí A, Smith GL. 1995. Vaccinia, cowpox and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J. Virol. 69:4633-39
82. Mossman K, Upton C, McFadden G. 1995. The myxoma virus-soluble interferon-γ receptor homolog, M-T7, inhibits interferon-γ in a species-specific manner. J. Biol. Chem. 270:3031-38
83. Puehler F, Weining KC, Symons JA, Smith GL, Staeheli P. 1998. Vaccinia virus-encoded cytokine receptor binds and neutralizes chicken interferon-gamma. Virology 248:231-40
84. Deleted in proof
85. Symons JA, Tscharke DC, Price N, Smith GL. 2002. A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J. Gen. Virol. 83:1953-64
86. Alcami A, Smith GL. 1996. Soluble interferon-gamma receptors encoded by poxviruses. Comp. Immunol. Microbiol. Infect. Dis. 19:305-17
87. Lalani AS, Graham K, Mossman K, Rajarathnam K, Clark-Lewis I, et al. 1997. The purified myxoma virus gamma interferon receptor homolog, M-T7, interacts with the heparin binding domains of chemokines. J. Virol. 71:4356-63
88. Alcami A, Smith GL. 2002. The vaccinia virus soluble interferon-gamma receptor is a homodimer. J. Gen. Virol. 83:545-49
89. Mossman K, Nation P, Macen J, Garbutt M, Lucas A, et al. 1996. Myxoma virus M-T7, a secreted homolog of the interferon-γ receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 215:17-30
90. Sroller V, Ludvikova V, Maresova L, Hainz P, Nemeckova S. 2001. Effect of IFN-gamma receptor gene deletion on vaccinia virus virulence. Arch. Virol. 146:239-49
91. Verardi PH, Jones LA, Aziz FH, Ahmad S, Yilma TD. 2001. Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated in vivo without a concomitant reduction in immunogenicity. J. Virol. 75:11-18
92. Smith VP, Alcami A. 2002. Inhibition of interferons by ectromelia virus. J. Virol. 76:1124-34
93. Symons JA, Alcamí A, Smith GL. 1995. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 81:551-60
94. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RML. 1995. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon α transmembrane signaling. J. Biol. Chem. 270:15974-78
95. Smith G, Chan YS. 1991. Two vaccinia virus proteins structurally related to the interleukin-1 receptor and the immunoglobulin superfamily. J. Gen. Virol. 72:511-18
96. Liptáková H, Kontsekova E, Alcami A, Smith GL, Kontsek P. 1997. Analysis of an interaction between the soluble vaccinia virus-coded Type I interferon (IFN)-receptor and human IFN-α1 and IFN-α2. Virology 232:86-90
97. Vancova I, La Bonnadiere C, Kontsek P. 1998. Vaccinia virus protein B18R inhibits the activity and cellular binding of the novel type interferon-delta. J. Gen. Virol. 79:1647-49
98. Alcami A, Symons JA, Smith GL. 2000. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J. Virol. 74:11230-39
99. Morikawa S, Ueda Y. 1993. Characterization of vaccinia surface antigen expressed by recombinant baculovirus. Virology 193:753-61
100. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. 2001. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19:423-74
101. Gu Y, Kuida K, Tsutsui H, Ku G, Hsiao K, et al. 1997. Activation of interferon-gamma inducing factor mediated by interleukin-1 beta converting enzyme. Science 275:206-9
102. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, et al. 1999. Interleukin-18 binding proteins: A novel modulator of the Th1 cytokine response. Immunity 10:127-36
103. Aizawa Y, Akita K, Taniai M, Torigoe K, Mori T, et al. 1999. Cloning and expression of interleukin-18 binding protein. FEBS Lett. 445:338-42
104. Xiang Y, Moss B. 1999. IL-18 binding and inhibition of interferon γ induction by human poxvirus-encoded proteins. Proc. Natl. Acad. Sci. USA 96:11537-42
105. Xiang Y, Moss B. 2001. Correspondence of the functional epitopes of poxvirus and human interleukin-18-binding proteins. J. Virol. 75:9947-54
106. Calderara S, Xiang Y, Moss B. 2001. Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities. Virology 279:22-26
107. Xiang Y, Moss B. 2001. Determination of the functional epitopes of human interleukin-18-binding protein by site-directed mutagenesis. J. Biol. Chem. 276:17380-86
108. Born T, Morrison LA, Esteban DJ, VandenBos T, Thebeau LG, et al. 2000. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J. Immunol. 164:3246-54
109. Smith VP, Bryant NA, Alcamí A. 2000. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J. Gen. Virol. 81:1223-30
110. Shchelkunov SN, Totmenin AV, Babkin IV, Safronov PF, Ryazankina OI, et al. 2001. Human monkeypox and smallpox viruses: genomic comparison. FEBS Lett. 509:66-70
111. Tulman ER, Afonso CL, Lu Z, Zsak L, Kutish Gf, et al. 2001. Genome of lumpy skin disease virus. J. Virol. 75:7122-30
112. Smith CA, Farrah T, Goodwin RG. 1994. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959-62
113. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501
114. Xu X, Nash P, McFadden G. 2000. Myxoma virus expresses a TNF receptor homolog with two distinct functions. Virus Genes 21:97-109
115. Cunnion KM. 1999. Tumor necrosis factor receptors encoded by poxviruses. Mol. Genet. Metab. 67:278-82
116. Schreiber M, Rajarathnam K, McFadden G. 1996. Mxyoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNFα, but the dimer is a more potent TNF inhibitor. J. Biol. Chem. 271:13333-41
117. Loparev VN, Parsons JM, Knight JC, Panus JF, Ray CA, et al. 1998. A third distinct tumor necrosis factor receptor of orthopoxviruses. Proc. Natl. Acad. Sci. USA 95:3786-91
118. Smith CA, Davis T, Wignall JM, Din WS, Farrah T, et al. 1991. T2 open reading frame from Shope fibroma virus encodes a soluble form of the TNF receptor. Biochem. Biophys. Res. Commun. 176:335-42
119. Upton C, Macen JL, Schreiber M, McFadden G. 1991. Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence. Virology 184:370-82
120. Macen JL, Graham KA, Lee SF, Schreiber M, Boshkov LK, et al. 1996. Expression of the myxoma virus tumor necrosis factor receptor homologue (T2) and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes. Virology 218:232-37
121. Schreiber M, Sedger L, McFadden G. 1997. Distinct domains of M-T2, the myxoma virus TNF receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J. Virol. 71:2171-81
122. Sedger L, McFadden G. 1996. M-T2: A poxvirus TNF receptor homologue with dual activities. Immunol. Cell Biol. 74:538-45
123. Hu FQ, Smith CA, Pickup DJ. 1994. Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the Type II TNF receptor. Virology 204:343-56
124. Smith CA, Hu FQ, Smith TD, Richards CL, Smolak P, et al. 1996. Cowpox virus genome encodes a second soluble homologue of cellular TNF receptors, distinct from CrmB, that binds TNF but not LTα. Virology 223:132-47
125. Saraiva M, Alcami A. 2001. CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses. J. Virol. 75:226-33
126. Panus JF, Smith CA, Ray CA, Smith TD, Patel DD, et al. 2002. Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue. Proc. Natl. Acad. Sci. USA 99:8348-53
127. Reading PC, Khanna A, Smith GL. 2002. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence. Virology 292:285-98
128. Aguado B, Selmes IP, Smith GL. 1992. Nucleotide sequence of 21.8 kbp of variola major virus strain Harvey and comparison with vaccinia virus. J. Gen. Virol. 73:2887-902
129. Smith VP, Alcamí A. 2000. Expression of secreted cytokine and chemokine inhibitors by ectromelia virus. J. Virol. 74:8460-71
130. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, et al. 1990. The complete DNA sequence of vaccinia virus. Virology 179:247-66
131. Howard ST, Chan YC, Smith GL. 1991. Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumour necrosis factor receptor family. Virology 180:633-47
132. Alcamí A, Khanna A, Paul NL, Smith GL. 1999. Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors. J. Gen. Virol. 80:949-59
133. Paulose M, Bennett BL, Manning AM, Essani K. 1998. Selective inhibition of TNF-alpha induced cell adhesion molecular gene expression by tanapox virus. Microb. Pathog. 25:33-41
134. Gil J, Rullas J, Alcami J, Esteban M. 2001. MC159L protein from the poxvirus molluscum contagiosum virus inhibits NF-kappa B activation and apoptosis induced by PKR. J. Gen. Virol. 82:3027-34
135. Oie KL, Pickup DJ. 2001. Cowpox virus and other members of the orthopoxvirus genus interfere with the regulation of NF-kappa B activation. Virology 288:175-87
136. Alcami A, Smith GL. 1992. A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection. Cell 71:153-67
137. Spriggs MK, Hruby DE, Maliszewski CR, Pickup DJ, Sims JE, et al. 1992. Vaccinia and cowpox viruses encode a novel secreted interleukin-1 binding protein. Cell 71:145-52
138. Alcami A, Smith GL. 1996. A mechanism for the inhibition of fever by a virus. Proc. Natl. Acad. Sci. USA 93:11029-34
139. Murphy PM. 2001. Viral exploitation and subversion of the immune system through chemokine mimicry. Nature 2:116-22
140. Kotwal GJ. 2000. Poxviral mimicry of complement and chemokine system components: What's the end game? Immunol. Today 21:242-48
141. Lalani AS, Barrett J, McFadden G. 2000. Modulating chemokines: more lessons from viruses. Immunol. Today 21:100-6
142. Mahalingam S, Karupiah G. 2000. Modulation of chemokines by poxvirus infections. Curr. Opin. Immunol. 12:409-12
143. Rosenkilde MM, Walkhoer M, Luttichau HR, Schwartz TW. 2001. Virally encoded 7TM receptors. Oncogene 20:1582-93
144. Lalani AS, McFadden G. 1997. Secreted poxvirus chemokine binding proteins. J. Leukoc. Biol. 62:570-76
145. Seet BT, McFadden G. 2002. Viral chemokine-binding proteins. J. Leukoc. Biol. 72:24-34
146. Liu LY, Lalani A, Dai E, Seet B, Macauley C, et al. 2000. The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury. J. Clin. Invest. 105:1613-21
147. Graham KA, Lalani AS, Macen JL, Ness TL, Barry M, et al. 1997. The T1/35 kDa family of poxvirus secreted proteins bind chemokines and modulate leukocyte influx into virus infected tissues. Virology 229:12-24
148. Alcamí A, Symons JA, Collins PD, Williams TJ, Smith GL. 1998. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J. Immunol. 160:624-33
149. Smith CA, Smith TD, Smolak PJ, Friend D, Hagen H, et al. 1997. Poxvirus genomes encode a secreted soluble protein that preferentially inhibits β chemokine activity yet lacks sequence homology to known chemokine receptors. Virology 236:316-27
150. Lalani AS, Ness TL, Singh R, Harrison JK, Seet BT, et al. 1998. Functional comparisons among members of the poxvirus T1/35 kDa family of soluble CC-chemokine inhibitor glycoproteins. Virology 250:173-84
151. Burns JM, Dairaghi DJ, Deitz M, Tsang M, Schall TJ. 2002. Comprehensive mapping of poxvirus vCCI chemokine-binding protein - expanded range of ligand interactions and unusual dissociation kinetics. J. Biol. Chem. 277:2785-89
152. Seet BT, Singh R, Paavola C, Lau EK, Handel TM, et al. 2001. Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor. Proc. Natl. Acad. Sci. USA 98:9008-13
153. Beck CG, Studer C, Zuber JF, Demange BJ, Manning U, et al. 2001. The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site. J. Biol. Chem. 276:43270-76
154. Lalani AS, Masters J, Graham K, Liu L, Lucas A, et al. 1999. Role of the myxoma virus soluble CC-chemokine inhibitor glycoprotein, M-T1, during myxoma virus pathogenesis. Virology 256:233-45
155. Martinez-Pomares L, Thompson JP, Moyer RW. 1995. Mapping and investigation of the role in pathogenesis of the major unique secreted 35-kDa protein of rabbitpox virus. Virology 206:591-600
156. Seet BT, Barrett J, Robichaud J, Shilton B, Singh R, et al. 2001. Glyosaminoglycan-binding properties of the myxoma virus CC-chemokine inhibitor, M-T1. J. Biol. Chem. 276:30504-13
157. Carfi A, Smith CA, Smolak PJ, McGrew J, Wiley DC. 1999. Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus. Proc. Natl. Acad. Sci. USA 96:12379-83
158. Bugert JJ, Lohmuller C, Damon I, Moss B, Darai G. 1998. Chemokine homolog of molluscum contagiosum virus: sequence conservation and expression. Virology 242:51-59
159. Ishikawa-Mochizuki I, Kitaura M, Baba M, Nakayama T, Izawa D, et al. 1999. Molecular cloning of a novel CC chemokine, interleukin-11 receptor alpha-locus chemokine (ILC), which is located on chromosome 9p13 and a potential homologue of a CC chemokine encoded by molluscum contagiosum virus. FEBS Lett. 460:544-48
160. Krathwohl MD, Hromas R, Brown DR, Broxmeyer HE, Fife KH. 1997. Functional characterization of the C-C chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. Proc. Natl. Acad. Sci. USA 94:9875-80
161. Damon I, Murphy PM, Moss B. 1998. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc. Natl. Acad. Sci. USA 95:6403-7
162. Luttichau BH, Stine J, Boesen TP, Johnsen AH, Chanry D, et al. 2000. A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus Molluscum Contagiosum. J. Exp. Med. 191:171-80
163. Luttichau HR, Gerstoft J, Schwartz TW. 2001. MC148 encoded by human molluscum contagiosum poxvirus is an antagonist for human but not murine CCRS. J. Leukoc. Biol. 70:277-82
164. Luttichau HR, Lewis IC, Gerstoft J, Schwartz TW. 2001. The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor. Eur. J. Immunol. 31:1217-20
165. deBruyne LA, Li K, Bishop DK, Bromberg JS. 2000. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther. 7:575-82
166. Knight JC, Novembre FJ, Brown DR, Goldsmith CS, Esposito JJ. 1989. Studies on Tanapox virus. Virology 172:116-24
167. Essani K, Chalasani S, Eversole R, Beuving L, Birmingham L. 1994. Multiple anti-cytokine activities secreted from tanapox virus-infected cells. Microb. Pathog. 17:347-53
168. Deane D, McInnes CJ, Percival A, Wood A, Thomson J, et al. 2000. Orf virus encodes a novel secreted protein inhibitor of granulocyte-macrophage colony-stimulating factor and interleukin-2. J. Virol. 74:1313-20
169. Ng A, Tscharke DC, Reading PC, Smith GL. 2001. The vaccinia virus A41L protein is a soluble 30 kDa glycoprotein that affects virus virulence. J. Gen. Virol. 82:2095-105
170. Spriggs MK. 1999. Shared resources between the neural and immune systems: semaphorins join the ranks. Curr. Opin. Immunol. 11:387-91
171. Tamagnone L, Comoglio PM. 2000. Signalling by semaphorin receptors: cell guidance and beyond. Cell Biol. 10:377-83
172. Kolodkin AL, Matthes DJ, Goodman CS. 1993. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. Cell 75:1389-99
173. Comeau MR, Johnson R, DuBose RF, Petersen M, Gearing P, et al. 1998. A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. Immunity 8:473-82
174. Ensser A, Fleckenstein B. 1995. Alcelaphine herpesvirus type 1 has a semaphorin-like gene. J. Gen. Virol. 76:1063-67
175. Gardner JD, Tscharke DC, Reading PC, Smith GL. 2001. Vaccinia virus semaphorin A39R is a 50-55 kDa secreted glycoprotein that affects the outcome of infection in a murine intradermal model. J. Gen. Virol. 82:2083-93
176. McFadden G, Graham K, Opgenorth A. 1994. Poxvirus growth factors. In In Viroceptors, Virokines and Related Immune Modulators Encoded by DNA Viruses, ed. G McFadden, pp. 1-15. Austin, TX: Landes
177. Stein RA, Staros JV. 2000. Evolutionary analysis of the ErbB receptor and ligand families. J. Mol. Evol. 50:397-412
178. Tzahar E, Moyer JD, Waterman H, Barbacci EG, Levkowitz G, et al. 1998. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17:5948-63
179. McFadden G, Moyer R. 2000. Poxvirus growth factors related to epidermal growth factor. In Cytokine Reference Database, ed. JJ Oppenheim, M Feldmann. http://www.academicpress.com/cytokinereference
180. Meyer M, Clauss M, Lepple-Wienhues A, Waltenberger J, Augustin H, et al. 1999. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (F1b-1) receptor tyrosine kinases. EMBO J. 18:363-74
181. Clauss M. 2000. Molecular biology of the VEGF and the VEGF receptor family. Semin. Thromb. Hemost. 26:561-69
182. McFadden G, Moyer R. 2000. Poxvirus vascular endothelial growth factor (VEGF) homologs of Orf virus. In Cytokine Reference Database, ed. JJ Oppenheim, M Feldmann. http://www.academicpress.com/cytokinereference
183. Savory LJ, Stacker SA, Fleming SB, Niven BE, Mercer AA. 2000. Viral vascular endothelial growth factor plays a critical role in orf virus infection. J. Virol. 74:10699-706
184. Wise LM, Veikkola T, Mercer AA, Savory LJ, Fleming SB, et al. 1999. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. USA 96:3071-76
185. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, et al. 2002. The interleukin-10 family of cytokines. Trends Immunol. 23:89-96
186. Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA. 1997. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J. Virol. 71:4857-61
187. Imlach W, McCaughan C, Mercer A, Haig D, Fleming S. 2002. Orf virus-encoded interleukin-10 stimulates the proliferation of murine mast cells and inhibits cytokine synthesis in murine peritoneal macrophages. J. Gen. Virol. 83:1049-58
188. Upton C, Macen JL, Wishart DS, McFadden G. 1990. Myxoma virus and malignant rabbit fibroma virus encode a serpin-like protein important for virus virulence. Virology 179:618-31
189. Nash P, Barry M, Seet BT, Veugelers K, Hota S, et al. 2000. Post-translational modification of the myxoma virus anti-inflammatory serpin, SERP-1 by a virally encoded sialyltransferase. Biochem. J. 347:375-82
190. Macen JL, Upton C, Nation N, McFadden G. 1993. SERP-1, a serine proteinase inhibitor encoded by myxoma virus, is a secreted glycoprotein that interferes with inflammation. Virology 195:348-63
191. Nash P, Whitty A, Handwerker J, Macen J, McFadden G. 1998. Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1. J. Biol. Chem. 273:20982-91
192. 1S by a myxoma virus serine proteinase inhibitor. J. Biol. Chem. 268:516-21
193. Zhou J, Sun XY, Fernando GJ, Frazer IH. 1992. The vaccinia virus K2L gene encodes a serine protease inhibitor which inhibits cell-cell fusion. Virology 189:678-86
194. Law KM, Smith GL. 1992. A vaccinia serine protease inhibitor which prevents virus-induced cell fusion. J. Gen. Virol. 73:549-57
195. Turner PC, Moyer RW. 1992. An Orthopoxvirus serpinlike gene controls the ability of infected cells to fuse. J. Virol. 66:2076-85
196. Turner PC, Baquero MT, Yuan S, Thoennes SR, Moyer RW. 2000. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasmiogen activators and plasmin. Virology 272:267-380
197. Turner PC, Moyer RW. 1995. Orthopoxvirus fusion inhibitor glycoprotein SPI-3 (open reading frame K2L) contains motifs characteristic of serine proteinase inhibitors that are not required for control of cell fusion. J. Virol. 69:5978-87
198. Wang YX, Turner PC, Ness TL, Moon KB, Schoeb TR, et al. 2000. The cowpox virus SPI-3 and myxoma virus SERP1 serpins are not functionally interchangeable despite their similar proteinase inhibition profiles in vitro. Virology 272:281-92
199. Hay S, Kannourakis G. 2002. A time to kill: viral manipulation of the cell death program. J. Gen. Virol. 83:1547-64
200. Roulston A, Marcellus RC, Branton PE. 1999. Viruses and apoptosis. Annu. Rev. Microbiol. 53:577-628
201. Hengartner MO. 2000. The biochemistry of apoptosis. Nature 407:770-76
202. Everett H, McFadden G. 1999. Apoptosis: An innate immune response to virus infection. Trends Microbiol. 7:160-65
203. Shisler JL, Moss B. 2001. Immunology 102 at poxvirus U: avoiding apoptosis. Semin. Immunol. 13:67-72
204. Barry M, McFadden G. 2000. Regulation of apoptosis by poxviruses. In Effects of Microbes on the Immune System, ed. M Cunningham, R Fujinami, pp. 509-20. Philadelphia: Lippincott-Raven
205. Everett H, McFadden G. 2002. Poxviruses and apoptosis: a time to die. Curr. Opin. Microbiol. 5:395-402
206. Bertin J, Armstrong RC, Ottilie S, Martin DA, Wang Y, et al. 1997. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc. Natl. Acad. Sci. USA 94:1772-76
207. Hu SM, Vincenz C, Buller M, Dixit VM. 1997. A novel family of viral death effector domain-containing molecules that inhibit both CD-95- and tumor necrosis factor receptor-1-induced apoptosis. J. Biol. Chem. 272:9621-24
208. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, et al. 1997. Viral FLICE-inhibitory proteins (vFLIPs) prevent apoptosis induced by death receptors. Nature 386:517-21
209. Shisler JL, Moss B. 2001. Molluscum contagiosum virus inhibitors of apoptosis: the MC159 v-FLIP protein blocks Fas-induced activation of procaspases and degradation of the related MC160 protein. Virology 282:14-25
210. Garvey TL, Bertin J, Siegel RM, Wang GH, Leonardo MJ, et al. 2002. Binding of FADD and Caspase-8 to molluscun contagiosum virus MC159 is not sufficient for its antiapoptotic function. J. Virol. 76:697-706
211. Ray CA, Black RA, Kronheim SR, Greenstreet TA, Sleath PR, et al. 1992. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1β converting enzyme. Cell 69:597-604
212. Thompson JP, Turner PC, Ali AN, Crenshaw BC, Moyer RW. 1993. The effects of serpin gene mutations on the distinctive pathobiology of cowpox and rabbitpox virus following intranasal inoculation of Balb/c mice. Virology 197:328-38
213. Quan LT, Caputo A, Bleackley RC, Pickup DJ, Salvesen GS. 1995. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J. Biol. Chem. 270:10377-79
214. Tewari M, Telford WG, Miller RA, Dixit VM. 1995. Crm A, a poxvirus-encoded serpin, inhibits cytotoxic T-lymphocyte-mediated apoptosis. J. Biol. Chem. 270:22705-8
215. Screpanti V, Wallin RP, Ljunggren HG, Grandien A. 2001. A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J. Immunol. 167:2068-73
216. Miura M, Zhu H, Rotello R, Hatweig EA, Yuan J. 1993. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75:653-60
217. Salvesen GS, Dixit VM. 1997. Caspases: intracellular signaling by proteolysis. Cell 91:443-46
218. Boudreau N, Sympson CJ, Werb Z, Bissell MJ. 1995. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 267:891-93
219. Gurevich RM, Regula KM, Kirshenbaum LA. 2001. Serpin protein CrmA suppresses hypoxia-mediated apoptosis of ventricular myocytes. Circulation 103:1984-91
220. Tewari M, Dixit VM. 1995. Fas- and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product. J. Biol. Chem. 270:3255-60
221. Enari M, Hug H, Nagata S. 1995. Involvement of an ICE-like protease in Fas-mediated apoptosis. Nature 375:78-81
222. Los M, Van deCraen M, Penning LC, Schenk H, Westendorp M, et al. 1995. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 375:81-83
223. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Litwack G, Alnemri ES. 1996. Molecular ordering of the Fas-apoptotic pathway: the Fas/APO-1 protease Mch5 is a CrmA-inhibitable protease that activates multiple Ced-3/ICE-like cysteine proteases. Proc. Natl. Acad. Sci. USA 93:14486-91
224. Komiyama T, Ray CA, Pickup DJ, Howard AD, Thornberry NA, et al. 1994. Inhibition of interleukin-1β converting enzyme by the cowpox virus serpin CrmA: an example of cross-class inhibition. J. Biol. Chem. 269:19331-37
225. Simonovic M, Gettins PGW, Volz K. 2000. Crystal structure of viral serpin crmA provides insights into its mechanism of cysteine proteinase inhibition. Protein Sci. 9:1423-27
226. Dobbelstein M, Shenk T. 1996. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J. Virol. 70:6479-85
227. Kettle S, Alcami A, Khanna A, Ehret R, Jassoy C, et al. 1997. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1β converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J. Gen. Virol. 78:677-85
228. Macen J, Takahashi A, Moon KB, Nathaniel R, Turner PC, et al. 1998. Activation of caspases in pig kidney cells infected with wild-type and CrmA/SPI-2 mutants of cowpox and rabbitpox viruses. J. Virol. 72:3524-33
229. Tscharke DC, Reading PC, Smith GL. 2002. Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J. Gen. Virol. 83:1977-86
230. Petit F, Bertagnoli S, Gelfi J, Fassy F, Boucraut-Baralon C, et al. 1996. Characterization of a myxoma virus-encoded serpin-like protein with activity against interleukin-1β converting enzyme. J. Virol. 70:5860-66
231. Messud-Petit F, Gelfi J, Delverdier M, Amardeilh M-F, Py R, et al. 1998. SERP-2, an inhibitor of the interleukin-1β-converting enzyme, is critical in the pathobiology of myxoma virus. J. Virol. 72:7830-39
232. Turner PC, Sancho MC, Theonnes SR, Caputo A, Bleackley RC, et al. 1999. Myxoma virus SERP-2 is a weak inhibitor of granzyme B and interleukin-1β -converting enzyme in vitro and unlike CrmA cannot block apoptosis in cowpox virus-infected cells. J. Virol. 73:6394-404
233. Gil J, Esteban M. 2000. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 5:107-14
234. Davies MV, Chang H-W, Jacobs BL, Kaufman RJ. 1993. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J. Virol. 67:1688-92
235. Kibler KV, Shors T, Perkins KB, Zeman CC, Banaszak MP, et al. 1997. Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J. Virol. 71:1992-2003
236. Ezelle HJ, Balachandran S, Sicheri F, Polyak SJ, Barber GN. 2001. Analyzing the mechanisms of interferon-induced apoptosis using CrmA and hepatitis C virus NS5A. Virology 281:124-37
237. Shisler JL, Senkevich TG, Berry MJ, Moss B. 1998. Ultraviolet-induced cell death blocked by a selenoprotein from a human dermatotropic poxvirus. Science 279:102-5
238. Brick DJ, Burke RD, Schiff L, Upton C. 1998. Shope fibroma virus Ring finger protein N1R binds DNA and inhibits apoptosis. Virology 249:42-51
239. Brick DJ, Burke RD, Minckley AA, Upton C. 2000. Ectromelia virus virulence factor p28 acts upstream of caspase-3 in response to UV light-induced apoptosis. J. Gen. Virol. 81:1087-97
240. Everett H, McFadden G. 2001. Viruses and apoptosis: meddling with mitochondria. Virology 288:1-7
241. Opgenorth A, Graham K, Nation N, Strayer D, McFadden G. 1992. Deletion analysis of two tandemly arranged virulence genes in myxoma virus, M11L and myxoma growth factor. J. Virol. 66:4720-31
242. Everett H, Barry M, Lee SF, Sun XJ, Graham K, et al. 2000. M11L: A novel mitochondria-localized protein of myxoma virus that blocks apoptosis in infected leukocytes. J. Exp. Med. 191:1487-98
243. Wasilenko ST, Meyers AF, Vander Helm K, Barry M. 2001. Vaccinia virus infection disarms the mitochondrion-mediated pathway of the apoptotic cascade by modulating the permeability transition pore. J. Virol. 75:11437-48
244. Barry M, Hnatiuk S, Mossman K, Lee S-F, Boshkov L, et al. 1997. The myxoma virus M-T4 gene encodes a novel RDEL-containing protein that is retained within the endoplasmic reticulum and is important for the productive infection of lymphocytes. Virology 239:360-77
245. Hnatiuk S, Barry M, Zeng W, Liu LY, Lucas A, et al. 1999. Role of the C-terminal RDEL motif of the myxoma virus M-T4 protein in terms of apoptosis regulation and viral pathogenesis. Virology 263:290-306
246. Mossman K, Lee SF, Barry M, Boshkov L, McFadden G. 1996. Disruption of MT5, a novel myxoma virus gene member of the poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits. J. Virol. 70:4394-410
247. Ink BS, Gilbert CS, Evans GI. 1995. Delay of vaccinia virus-induced apoptosis in nonpermissive Chinese hamster ovary cells by the cowpox virus CHOhr and adenovirus E1B 19K genes. J. Virol. 69:661-68
248. Barber GN. 2001. Host defence, viruses and apoptosis. Cancer Death Differ. 8:113-26
249. Jacobs BL, Langland JO. 1996. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology 219:339-49
250. Chang H-W, Watson JC, Jacobs BL. 1992. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA 89:4825-29
251. Sharp TV, Moonan F, Romashko A, Joshi B, Barber GN, et al. 1998. The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR - implications for PKR autoregulation. Virology 250:302-15
252. Smith EJ, Marie I, Prakash A, Garcia-Sastre A, Levy DE. 2001. IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or I kappa B kinase but is blocked by vaccinia virus E3L protein. J. Biol. Chem. 276:8951-57
253. Liu Y, Wolff KC, Jacobs BL, Samuel CE. 2001. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity. Virology 289:378-87
254. Rogan S, Heaphy S. 2000. The vaccinia virus E3L protein interacts with SUMO-1 and ribosomal protein L23a in a yeast two hybrid assay. Virus Genes 21:193-95
255. Xiang Y, Condit RC, Vijaysri S, Jacobs B, Williams BR, et al. 2002. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J. Virol. 76:5251-59
256. Beattie E, Tartaglia J, Paoletti E. 1991. Vaccinia virus-encoded eIF-2α homolog abrogates the antiviral effect of interferon. Virology 183:419-22
257. Carroll K, Elroystein O, Moss B, Jagus R. 1993. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent, initiation factor-2-alpha-specific protein kinase. J. Biol. Chem. 268:12837-42
258. Beattie E, Denzler KL, Tartaglia J, Perkus ME, Paoletti E, et al. 1995. Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J. Virol. 69:499-505
259. Beattie E, Kauffman EB, Martinez H, Perkus ME, Jacobs BL, et al. 1996. Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes 12:89-94
260. Brandt TA, Jacobs BL. 2001. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J. Virol. 75:850-56
261. McInnes CJ, Wood AR, Nettleton PF, Gilray JA. 2001. Genomic comparison of an avirulent strain of orf virus with that of a virulent wild type isolate reveals that the orf virus G2L gene is non-essential for replication. Virus Genes 22:141-50
262. McInnes CJ, Wood AR, Mercer AA. 1998. Orf virus encodes a homolog of the vaccinia virus interferon resistance gene E3L. Virus Genes 17:107-15
263. Kawagishi-Kobayashi M, Cao CN, Lu JM, Ozato K, Dever TE. 2000. Pseudo-substrate inhibition of protein kinase PKR by swine pox virus C8L gene product. Virology 276:424-34
264. Fang Z-Y, Limbach K, Tartaglia J, Hammonds J, Chen X, et al. 2001. Expression of vaccinia E3L and K3L genes by a novel recombinant canarypox HIV vaccine vector enhances HIV-1 pseudovirion production and inhibits apoptosis in human cells. Virology 291:272-84
265. Najarro P, Traktman P, Lewis JA. 2001. Vaccinia virus blocks gamma interferon signal transduction: Viral VH1 phosphatase reverses Stat1 activation. J. Virol. 75:3185-96
266. O'Neill L. 2000. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem. Soc. 28:557-63
267. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, et al. 2000. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc. Natl. Acad. Sci. USA 97:10162-67
268. Lucas A, Liu L, Macen J, Nash P, Dai E, et al. 1996. Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 94:2890-900
269. Miller L, Dai E, Nash P, Liu L, Icton C, et al. 2000. Inhibition of transplant vasculopathy in a rat aortic model after infusion of an anti-inflammatory viral serpin. Circulation 101:1598-605
270. Hausen B, Boeke K, Berry GJ, Morris RE. 2001. Viral serine proteinase inhibitor (Serp-1) effectively decreases the incidence of graft vasculopathy in heterotopic heart allografts. Transplantation 72:364-68
271. Maksymowych WP, Nation N, Nash PD, Macen J, Lucas A, et al. 1996. Amelioration of antigen-induced arthritis in rabbits treated with a secreted viral serine proteinase inhibitor. J. Rheumatol. 23:878-82
272. Dabbagh K, Xiao Y, Smith C, Stepick-Biek P, Kim SG, et al. 2000. Local blockade of allergic airway hyperreactivity and inflammation by the poxvirus-derived pan-CC-chemokine inhibitor vCCI. J. Immunol. 165:3418-22
273. DeBruyne LA, Li K, Bishop DK, Bromberg JS. 2000. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity. Gene Ther. 7:575-82
274. Afonso CL, Tulman ER, Lu Z, Zsak L, Sandybaev NT, et al. 2002. The genome of camelpox virus. Virology 295:1-9
275. Shchelkunov SN, Safronov PF, Totmenin AV, Petrov NA, Ryazankina OI, et al. 1998. The genomic sequence analysis of the left and right species-specific terminal region of a cowpox virus strain reveals unique sequences and a cluster of intact ORFs for immunomodulatory and host range proteins. Virology 243:432-60
276. Shchelkunov SN, Totmenin AV, Safronov PF, Mikheev MV, Gutorov VV, et al. 2002. Analysis of the monkeypox virus genome. Virology 297:172-94
277. Shchelkunov SN, Blinov VM, Sandakhchiev LS. 1993. Genes of variola and vaccinia viruses necessary to overcome the host protective mechanism. FEBS Lett. 319:80-83